Internal Server Error

ImpriMed - About the company

ImpriMed is a series A company based in Palo Alto (United States), founded in 2017 by Hye Ryeon Lee, Jamin Koo and Sungwon Lim. It operates as a Provider of precision medicines for veterinary cancer. ImpriMed has raised $44.9M in funding from investors like Plug and Play Tech Center, SK Telecom and LB Investment. The company has 9 active competitors, including 5 that are funded. Its top competitors include companies like QBiotics, VetDC and Animal Life Sciences.

Company Details

Provider of precision medicines for veterinary cancer. The company offers different drug combinations suited for a certain cancer pet patient. The company biopsies the live cancer cells for drug responses before treatment. Based on these responses, the company uses its data-driven technology to help veterinary oncologists to fix a personalized medicinal regime for an individual.
Email ID
*****@imprimedicine.com
Registered Address
4030 Fabian Way Palo Alto, CA 94303
Key Metrics
Founded Year
2017
Location
Palo Alto, United States
Stage
Series A
Total Funding
$44.9M in 6 rounds
Latest Funding Round
Ranked
Employee Count
45 as on Oct 31, 2026
Similar Companies
Sign up to download ImpriMed's company profile

ImpriMed's funding and investors

ImpriMed has raised a total funding of $44.9M over 6 rounds. Its first funding round was on Jun 2018. Its latest funding round was a Series A round on Sep 18, 2026 for $*****. 5 investors participated in its latest round. ImpriMed has 32 institutional investors.

Here is the list of recent funding rounds of ImpriMed:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Sep 18, 2026
1090097
Series A
3056053
9839779
4270349
5716802
Nov 06, 2023
4629431
Series A
3116218
1505488
1467460
Apr 13, 2021
1654642
Grant (prize money)
4151841
5491578
1944883
4104178
lockAccess funding benchmarks and valuations. Sign up today!

ImpriMed's founders and board of directors

Founder? Claim Profile
The founders of ImpriMed are Hye Ryeon Lee, Jamin Koo and Sungwon Lim. Sungwon Lim is the CEO of ImpriMed.
Here are the details of ImpriMed's key team members:

ImpriMed's employee count trend

ImpriMed has 45 employees as of Oct 26. Here is ImpriMed's employee count trend over the years:
Employee count trend for ImpriMed
lockUncover ImpriMed's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

ImpriMed's Competitors and alternates

Top competitors of ImpriMed include QBiotics, VetDC and Animal Life Sciences. Here is the list of Top 10 competitors of ImpriMed, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for ImpriMed
ImpriMed
2017, Palo Alto (United States), Series A
Provider of precision medicines for veterinary cancer
$44.9M
49/100
2nd
Logo for QBiotics
QBiotics
2000, Brisbane (Australia), Series C
Developer of small molecules discovered from the plant extracts
$98.1M
42/100
3rd
Logo for VetDC
VetDC
2010, Fort Collins (United States), Series A
Developing advanced cancer treatments for pets, enhancing their quality of life
$5.51M
37/100
4th
Logo for Animal Life Sciences
Animal Life Sciences
2018, New York City (United States), Seed
Developer of pet food, supplements and therapeutics to treat cancer in animals
$199K
-
26/100
5th
Logo for Vetco Pharmaceuticals
Vetco Pharmaceuticals
2012, Sanchong (Taiwan), Unfunded
Provider of pharmaceutical products for treating cancer in animals
-
-
24/100
6th
Logo for CanFel Therapeutics
CanFel Therapeutics
1999, Torrance (United States), Funding Raised
Developer of therapeutics for treating cancer in animals
-
23/100
7th
Logo for BioTesserae
BioTesserae
2022, Corvallis (United States), Seed
Company developing nanobody-based therapies for canine cancer treatment for pet health
$100K
23/100
8th
Logo for MT3
MT3
2018, Minato (Japan), Funding Raised
Developer of therapeutics for cancer treatment in animals
-
21/100
9th
Logo for Kyrexa
Kyrexa
2023, Edinburgh (United Kingdom), Unfunded
Developer of pharmaceutical treatments for managing cancer in domestic animals
-
-
16/100
10th
Developer of veterinary therapeutics for the treatment of cancer
-
-
15/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on ImpriMed's competitors? Click here to see the top ones

ImpriMed's Investments and acquisitions

ImpriMed has made no investments or acquisitions yet.

Reports related to ImpriMed

Here is the latest report on ImpriMed's sector:

News related to ImpriMed

lockFilter this list
Media has covered ImpriMed for 1 event in last 1 year.
•
ImpriMed Raises $8M in Pre-Series A FundingFinSMEs•Apr 15, 2021•ImpriMed, HGI, Draper, Draper Dragon and 7 others
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about ImpriMed

Explore our recently published companies
  • PaddleSmash - United States based, 2021 founded, Unfunded company
  • CEP CEC - New Orleans based, Unfunded company
  • Utseende - Norway based, Unfunded company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford